BARCELONA, Spain—In patients with acute coronary syndromes (ACS), the oral, reversible antiplatelet agent ticagrelor is superior to clopidogrel in reducing ischemic events, without any increase in ...

The antiplatelet agent ticagrelor (Brilinta/Brilique, AstraZeneca) demonstrated bactericidal activity against antibiotic-resistant gram-positive bacteria that pose a threat to human health, including ...

Despite a higher incidence of dyspnea among patients with acute coronary syndromes (ACS) on ticagrelor compared with clopidogrel, the side effect is usually not serious and resolves spontaneously or ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio ANAHEIM, Calif. — Patients undergoing ...

Please provide your email address to receive an email when new articles are posted on . Among patients with STEMI who underwent PCI with an ultrathin bioresorbable polymer sirolimus-eluting stent, ...

After one month of dual antiplatelet therapy (DAPT) with aspirin and ticagrelor (Brilinta) post-percutaneous coronary intervention for an acute coronary syndrome, dropping aspirin cut bleeding risk ...

Since the start of 2011, the active ingredient ticagrelor can be prescribed in Germany in addition to acetylsalicylic acid to avoid blood clots in patients with acute ischaemia of the cardiac muscle.

A clinical trial evaluated whether adding ticagrelor to aspirin improves outcomes for patients with stable coronary artery disease and diabetes mellitus but without a history of heart attack or stroke ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of extended therapy with ticagrelor 60 mg twice daily plus aspirin (hereafter referred to as ticagrelor), ...

Ticagrelor (Brilique, AstraZeneca) is an oral antagonist at the P2Y 12 adenosine diphosphate receptor, which inhibits platelet aggregation and thrombus formation in atherosclerotic disease. The ...